Systemic Inflammatory Markers Predicting the Overall Survival of Patients Using Tyrosine Kinase Inhibitors in the First-line Treatment of Metastatic Renal Cell Carcinoma

Basit Öğe Kaydı
dc.contributor.authorKorkmaz, Mustafa
dc.contributor.authorErylmaz, Melek Karakurt
dc.date.accessioned2024-02-23T14:34:24Z
dc.date.available2024-02-23T14:34:24Z
dc.date.issued2023
dc.departmentNEÜen_US
dc.description.abstractObjective: To identify prognostic inflammatory markers in metastatic renal cell carcinoma (mRCC) patients who received anti-vascular endothelial growth factor receptor (VEGFR) agents. Study Design: Observational study. Place and Duration of the Study: Department of Medical Oncology, Necmettin Erbakan University, Meram Medical Faculty, Konya, Turkey, between January 2015 and December 2021. Methodology: A total of 110 patients with mRCC who received sunitinib or pazopanib for at least 3 months were enrolled. Hemogram, C-reactive protein (CRP) and albumin values of the patients, CRP to albumin ratio (CAR), neutrophil-lymphocyte ratio (NLR), platelet -lym-phocyte ratio (PLR), systemic immune-inflammation index (SII), prognostic nutrition index (PNI) and systemic inflammatory response indexes (SIRI) were calculated and recorded. Progression-free survival and overall survival analyses of the patients were performed using the Kaplan-Meier method. Cox regression method was used to identify prognostic factors. Variables found to be significant in univariate analysis were enrolled in multivariate analysis. Results: In the univariate analysis for median overall survival (mOS), whether or not surgery was applied as the primary treatment option, grade, lymphovascular invasion (LVI), International Metastatic RCC Database Consortium (IMDC) score, CAR, NLR, PLR, SII, PNI and SIRI were found to be statistically significant. Systemic inflammation markers (CAR, NLR, PLR, PNI, SII and SIRI) were found to be independent prognostic markers for mOS as a result of Cox multivariate analysis. Conclusion: CAR, NLR, PLR, SII, PNI, and SIRI values measured before anti-VEGFR treatment in patients with mRCC may be of addi-tional prognostic significance. These markers, which are calculated by using parameters that are always measured in routine practice, such as complete blood count (CBC), albumin, and CRP levels, are easy and inexpensive methods that give an idea about the course of the disease.en_US
dc.identifier.doi10.29271/jcpsp.2023.06.653
dc.identifier.endpage658en_US
dc.identifier.issn1022-386X
dc.identifier.issn1681-7168
dc.identifier.issue6en_US
dc.identifier.pmid37300261en_US
dc.identifier.scopus2-s2.0-85161680927en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage653en_US
dc.identifier.urihttps://doi.org/10.29271/jcpsp.2023.06.653
dc.identifier.urihttps://hdl.handle.net/20.500.12452/15593
dc.identifier.volume33en_US
dc.identifier.wosWOS:001011668000011en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherColl Physicians & Surgeons Pakistanen_US
dc.relation.ispartofJcpsp-Journal Of The College Of Physicians And Surgeons Pakistanen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectSunitiniben_US
dc.subjectPazopaniben_US
dc.subjectRenal Cell Carcinomaen_US
dc.subjectPrognostic Markeren_US
dc.subjectOverall Survivalen_US
dc.subjectInflammatoryen_US
dc.titleSystemic Inflammatory Markers Predicting the Overall Survival of Patients Using Tyrosine Kinase Inhibitors in the First-line Treatment of Metastatic Renal Cell Carcinomaen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu